JY
MLYS icon

Jeff Yass’s Mineralys Therapeutics MLYS Stock Holding History

Jeff Yass’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.82M Sell
178,600
-547,300
-75% -$15M ﹤0.01% 4687
2026
Q1 		$19.7M Buy
725,900
+155,100
+27% +$4.55M ﹤0.01% 2245
2025
Q4 		$20.7M Buy
570,800
+533,800
+1,443% +$21.4M ﹤0.01% 2162
2025
Q3 		$1.4M Buy
37,000
+12,000
+48% +$260K ﹤0.01% 6548
2025
Q2 		$338K Buy
25,000
+7,200
+40% +$104K ﹤0.01% 10069
2025
Q1 		$283K Buy
+17,800
New +$205K ﹤0.01% 10185

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jeff Yass's MLYS Position: Q2 2026 in Review

Jeff Yass increased its Mineralys Therapeutics (MLYS) stake by 2,155% in Q2 2026, buying an estimated $9.32M and bringing the position to 355,570 shares worth $9.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3474.

Jeff Yass first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Jeff Yass held 355,570 shares of Mineralys Therapeutics worth $9.59M as of Q2 2026.
  • Jeff Yass bought 339,800 Mineralys Therapeutics shares in Q2 2026, an estimated $9.32M.
  • Mineralys Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3474 holding.
  • Jeff Yass first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.